AUA
  • Program
  • Register
  • Meeting Coverage
  • Guidelines
  • Industry Highlights
  • Science & Technology Hall
  • Photo Gallery
Topics
  • Meeting Coverage
  • Guidelines
  • Industry Highlights
  • Science & Technology Hall
  • Photo Gallery
Resources
  • Program
  • Register
Twitter X icon Facebook iconInstagram iconYouTube iconLinkedIn icon
Apr 28, 2025

Renal stone care reimagined

PUSH, laser comparison and stent omission trials reveal surprising insights, challenging long-held practices and offering new guidance for managing renal stones at every stage.


Margaret Knoedler, MD
Margaret Knoedler, MD

A trio of practice-changing, paradigm-shifting (P2) clinical trials is affecting the management of renal stones. Increasing fluid intake does not improve stone-free outcomes, YAG and thulium fiber lasers provide similar results, and patients are happier without stents following uncomplicated ureteroscopy for renal stones.

Results for the three trials were discussed during the Plenary on Sunday morning.Alana Desai, MDAlana Desai, MD

The PUSH (prevention of urinary stones with hydration) trial was the largest stone intervention trial to date, reported Alana Desai, MD, clinical associate professor of urology at the University of Washington. A total of 1,658 participants across six clinical centers in the U.S. were randomized to usual care or behavioral interventions designed to improve fluid intake after stone surgery. Participants were followed for 24 months.

"Increased fluid intake is universally recommended to decrease the risk of recurrent stone disease," Dr. Desai said. “However, the effectiveness of interventions to maintain high fluid intake has not been well studied. Adherence is critical but challenging. How do you change a behavior?”

The trial used financial incentives and structured problem-solving to boost fluid intake, and a wireless smart water bottle to assess fluid intake. Fluid intake target was ≥2.5 L for adults or 30 mL/kg/day for adolescents. 

Dr. Desai reported no difference in symptomatic recurrence of urinary stone disease between the two groups. The intervention group had a significant increase in urine output, but neither group achieved average fluid intake at or above guideline volumes.

Ureteroscopy surpassed shockwave lithotripsy as the most common stone surgery in 2017, but there have been few direct comparisons between different laser devices for dusting stones. What may be the first head-to-head clinical trial of high-powered Holmium:YAG and high-powered thulium fiber lasers found similar outcomes.

“We have 107 patients with post-operative data so far, and stone-free rates do not differ between the two groups,” reported Margaret Knoedler, MD, associate professor of urology and chief of endourology at the University of Wisconsin School of Medicine and Public Health. “Quality of life postoperatively was similar between the two lasers. Both high-powered lasers are effective and safe at treating renal stones, and the choice of laser system can be left up to the surgeon and the hospital system.”

The most recent randomized controlled trial of stenting vs. not stenting following uncomplicated ureteroscopy for renal stones found significantly less pain when stents were omitted. There was no difference in emergency department visits or other unplanned health care utilization, but patient satisfaction was much higher without stenting.

When patients were asked if they would repeat the procedure for another stone, 52% of unstented patients said they would definitely repeat treatment compared to 19% for the stented group.Seth Bechis, MDSeth Bechis, MD

“We clearly see a preference for avoiding stents,” said Seth Bechis, MD, associate professor of urology at the University of California San Diego. “I would urge all of you performing a ureteroscopy for an uncomplicated case to consider not leaving a stent. Your patients will have a better quality of life, and we found no difference in unplanned encounters.”

Interesting Stories
Book your AUA2025 housing now
Sponsored by AUA
Book your AUA2025 housing now
Register for the Career Fair at AUA2025
Sponsored by AUA
Register for the Career Fair at AUA2025
YONSA® (abiraterone acetate) Holds a Full House of Benefits—See Booth 1222
Sponsored by Sun Pharma
YONSA® (abiraterone acetate) Holds a Full House of Benefits—See Booth 1222
More Content
Getty Images 2212620732
Meeting Coverage
Thought-provoking takeaways from AUA2025
Jun 02, 2025
Getty Images 1203616323
Guidelines
Guidelines offer new directions in urological care
Jun 02, 2025
Getty Images 1397381715
Meeting Coverage
P2s at AUA2025: Clinical trials reshaping urology
Jun 02, 2025
Vin Gupta, MD, MPA
Meeting Coverage
Keynote call to action: Rethinking innovation in urology
Jun 02, 2025
K4 0795
Meeting Coverage
Meet your 2025 AUA Residents Bowl champions!
Jun 02, 2025
Siobhan Hartigan, MD
Meeting Coverage
Healthy debates
Jun 02, 2025
Dr. David Penson (fourth from left) and first-place winner (small program) Cedars-Sinai Urology Residency Program.
Meeting Coverage
Olympic gold
Jun 02, 2025
Mg 1067 is0 U4 Ai31z Copy
Meeting Coverage
Picture this
Jun 02, 2025
Getty Images 1356620786
Meeting Coverage
Save the date for AUA2026
Jun 02, 2025
Aua Readit xd2d B Aih Gz Copy
Meeting Coverage
Did you miss something?
Jun 02, 2025
Getty Images 1285476518
Meeting Coverage
AUA2025: By the numbers
May 13, 2025
Getty Images 2196976767
Meeting Coverage
Claim your CME
May 13, 2025
AUA
Twitter X icon Facebook iconInstagram iconYouTube iconLinkedIn icon
© 2025 Ascend Media. All rights reserved.